Genome-wide association study identifies a common variant associated with risk of endometrial cancer

- Spurdle, Amanda B., Thompson, Deborah J., Fahey, Paul, Montgomery, Grant W., Webb, Penelope M., Fasching, Peter A., Beckmann, Matthias W., Ekici, Arif B., Hein, Alexander, Lambrechts, Diether, Coenegrachts, Lieve, Vergote, Ignace, Ahmed, Shahana, Amant, Frederic, Salvesen, Helga B., Trovik, Jone, Njolstad, Tormund S., Helland, Harald, Scott, Rodney J., Ashton, Katie, Proietto, Tony, Otton, Geoffrey, National Study of Endometrial Cancer Genetics Group,, Ferguson, Kaltin, Tomlinson, Ian, Gorman, Maggie, Howarth, Kimberley, Hodgson, Shirley, Garcia-Closas, Montserrat, Wentzensen, Nicolas, Yang, Hannah, Chanock, Stephen, Hall, Per, Czene, Kamila, Healey, Catherine S., Liu, Jianjun, Li, Jingmei, Shu, Xiao-Ou, Zheng, Wei, Long, Jirong, Xiang, Yong-Bing, Shah, Mitul, Morrison, Jonathan, Michailidou, Kyriaki, Pharoah, Paul D., O'Mara, Tracy, Dunning, Alison M., Easton, Douglas F., Walker, Logan C,, Montgomery, Stephen B., Dermitzakis, Emmanouil T., Australian National Endometrial Cancer Study Group,

MRI-guided prostate radiation therapy planning: investigation of dosimetric accuracy of MRI-based dose planning

- Lambert, Jonathon, Greer, Peter B., Kumar, Mahesh, Dowling, Jason, Hauville, Sarah, Hughes, Cynthia, Fisher, Kristen, Lau, Peter, Denham, James W., Salvado, Olivier, Menk, Fred, Patterson, Jackie, Parker, Joel, Dahl, Kara, Gupta, Sanjiv, Capp, Anne, Wratten, Chris, Tang, Colin

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

Smad3 dosage determines androgen responsiveness and sets the pace of postnatal testis development

- Itman, Catherine, Wong, Chin, Hunyadi, Briony, Ernst, Matthias, Jans, David A., Loveland, Kate L.

Using linked routinely collected health data to describe prostate cancer treatment in New South Wales, Australia: a validation study

- Goldsbury, David E., Smith, David P., Armstrong, Bruce K., O'Connell, Dianne L.

Automatic MRI atlas-based external beam radiation therapy treatment planning for prostate cancer

- Dowling, Jason, Lambert, Jonathon, Parker, Joel, Greer, Peter B., Fripp, Jurgen, Denham, James, Ourselin, Sébastien, Salvado, Olivier

Cancer biomarker discovery: the entropic hallmark

- Berretta, Regina, Moscato, Pablo

The migration and invasion of human prostate cancer cell lines involves CD151 expression

- Ang, Jian, Fang, Bing-Liang, Ashman, Leonie K., Frauman, Albert G.

Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?

- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.

Novel biomarkers for prostate cancer revealed by (α,β)-k-feature sets

- Ravetti, Martin Gómez, Berretta, Regina, Moscato, Pablo

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter)

- Lamb, David S., Delahunt, Brett, Denham, James, Slaney, David

The role and implications of the Internet in healthcare delivery

- Broom, Alex

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine

Microarrays: identifying molecular portraits in prostrate tumors with different Gleason patterns

- Mendes, Alexandre, Scott, Rodney J., Moscato, Pablo

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer

- Duke, Janine M., Treloar, C. J., Byles, Julie E.

A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate

- Lamb, David, Joesph, David, Turner, Sandra, Diamond, Terry, Steigler, Allison, Attia, John, Delahunt, Brett, Haworth, Annette, Denham, Jim, Duchesne, Gillian, Atkinson, Chris, Kenny, Lizbeth, Gogna, Kumar, Matthews, John, Spry, Nigel, Tai, Keen-Hun